By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
GLP-1 medications work while you take them. When you stop, appetite and weight tend to return: in the STEP 1 trial extension, adults regained about two-thirds of their lost weight in the year after stopping semaglutide, with cardiometabolic improvements drifting back toward baseline.
GLP-1 medications work while you take them. When you stop, appetite and weight tend to return: in the STEP 1 trial extension, adults regained about two-thirds of their lost weight in the year after stopping semaglutide, with cardiometabolic improvements drifting back toward baseline.
GLP-1 medications work while you take them. When you stop, appetite and weight tend to return: in the STEP 1 trial extension, adults regained about two-thirds of their lost weight in the year after stopping semaglutide, with cardiometabolic improvements drifting back toward baseline.
What Happens If You Pause or Stop GLP-1 Support: The Maintenance Decision, Explained
What Happens If You Pause or Stop GLP-1 Support: The Maintenance Decision, Explained
Weight Loss (GLP-1, maintenance)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Weight Loss (GLP-1, maintenance)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Weight Loss (GLP-1, maintenance)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Key takeaways
GLP-1 receptor agonists work by continuously replacing a hormone signal your body makes after eating. When the medication stops, the signal stops — which is why appetite and weight tend to return rather than stay fixed in place.
In the STEP 1 trial extension, people who stopped semaglutide regained about two-thirds of their lost weight within a year, and most of the cardiometabolic improvements drifted back toward baseline (Wilding 2022).
This is increasingly understood as the biology of a chronic condition, not a personal failure. The honest question is not "how do I get off this?" but "what does the maintenance phase look like, and who is monitoring it?"
There is a real difference between stopping abruptly and tapering under supervision — with attention to protein, resistance training, body composition, and labs. The plan around the decision is what matters most.
When GLP-1 therapy stops, the hormonal signal it replaces stops with it — and for most people, appetite and weight return. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight in the year after stopping semaglutide, with most cardiometabolic improvements drifting back toward baseline (Wilding 2022).
If you are on a GLP-1 medication and the question in the back of your mind is "do I have to be on this forever?" — you are asking the most honest question in weight care. It is the single most common concern competitor pages now lead with, and for good reason. Nobody wants to feel tethered to a weekly injection indefinitely.
The reflex answer from the internet is either reassurance or alarm. The clinical reality is more useful than either: these medications were designed for ongoing use, the evidence on abrupt stopping is clear and not especially comforting, and there is a meaningful difference between walking away from the medication and stepping down from it with a plan. This is a guide to that decision — what the trials actually show, and what a monitored maintenance phase looks like.
Why These Medications Work Only While You Take Them
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It does several things at once: it slows the rate at which your stomach empties, it signals fullness to the brain, and it quiets the background "food noise" — the low-grade preoccupation with the next meal that drives much of overeating. Semaglutide is an engineered version of this GLP-1 signaling; tirzepatide acts on the GLP-1 receptor and a second related receptor (GIP). Both are built to last about a week per dose instead of minutes.
Here is the part that explains everything about stopping. The medication does not retrain your physiology to a new permanent set point. It supplies a signal that your body, in a state of excess weight, does not produce strongly enough on its own. While the drug is present, appetite is lower and the food noise is quieter. When the drug clears, the underlying signaling returns to where it was — and so, for most people, do appetite and weight. The biological story is simple: the medication manages the condition; it does not cure it.
This is why endocrinologists increasingly frame obesity the way they frame hypertension or type 2 diabetes — as a chronic condition where the treatment works for as long as it is used, not a course you complete (Endocrine Society clinical practice guideline, 2015). A blood pressure medication is not a failure because the numbers rise again after you stop it. The same logic applies here.
What the Trials Show When People Stop
Three randomized trials have looked directly at what happens when GLP-1 therapy is continued versus withdrawn. The evidence is consistent.
In the STEP 1 trial extension, adults who had lost an average of 17.3% of their body weight on semaglutide had the medication and the lifestyle support withdrawn, then were followed for another year. They regained 11.6 percentage points of the weight they had lost — roughly two-thirds of it — leaving a net loss of about 5.6% from where they started. Improvements in blood pressure, lipids, and blood sugar largely reverted toward baseline over the same period (Wilding 2022, PMID 35441470). The trial's own authors concluded that the findings "confirm the chronicity of obesity" and that ongoing treatment is required to maintain the benefit.
Two withdrawal trials show the mirror image — what continuing does. In SURMOUNT-4, participants who reached an average 20.9% weight reduction over a 36-week open-label lead-in on tirzepatide were randomized either to stay on it or switch to placebo for a year. Those who continued lost a further 5.5%; those who switched to placebo regained 14.0% (Aronne 2024, PMID 38078870). Nearly nine in ten people who stayed on treatment held onto at least 80% of their initial loss, versus about one in six who stopped. STEP 4 found the same pattern with semaglutide: over the 48 weeks after randomization, continuing produced a further 7.9% loss, while switching to placebo produced a 6.9% weight gain, with waist circumference and blood pressure tracking in the same direction (Rubino 2021, PMID 33755728).
Two important caveats keep this honest. These are averages, and individual variation is considerable — some people hold their weight better than the means suggest, and a smaller number do worse. And the regain seen in these trials followed abrupt discontinuation with limited structured support; it is not a verdict on what a planned, monitored step-down can achieve, which has been less studied. What the data do establish is the direction: for most people, the weight comes back when the signal goes away.
Pause, Taper, or Stop — How the Decision Actually Gets Made
"Stopping" is not one decision. In practice there are three distinct paths, and the right one depends on why someone wants off and where they are in their progress.
Continue at a maintenance dose. For many people who have reached their goal, the appropriate move is not to stop but to settle onto the lowest dose that holds the result. The maintenance phase is a real clinical stage, not a holding pattern — the aim is the smallest effective dose with the fewest side effects.
Taper under supervision. For those who do want to come off — because of cost, side effects, pregnancy planning, or simple preference — a gradual step-down is more sensible than an abrupt stop. Tapering gives the clinical team time to watch what happens to appetite, weight, and labs at each lower dose, and to pause the descent if regain accelerates. It also creates a window to reinforce the non-medication scaffolding that has to carry more of the load: protein, training, sleep, and structure. Because these medications are not used in pregnancy and clear slowly, manufacturer guidance is to stop semaglutide at least two months before a planned pregnancy (FDA prescribing information).
Stop, with a monitored landing. Sometimes stopping fully is the right call — a goal met and held, a side effect that outweighs the benefit, or a life circumstance that requires it. Even then, stopping is a managed process rather than an event. A reasonable question to ask any prescribing program at the start is what stepping down or stopping would look like — the answer is part of how you choose where to get care.
Cost and access changes are common reasons patients consider stopping — a physician-led program should help you evaluate whether a lower maintenance dose, a therapeutic switch, or a supervised step-down best fits your situation, and confirm you are on an FDA-approved product.
When Stopping Is the Medically Right Call
Some situations make pausing or stopping the medically appropriate choice, and a good program names them up front. Stopping is warranted for persistent or severe gastrointestinal symptoms, suspected pancreatitis, gallbladder disease, or severe gastroparesis, and the medication should be stopped when pregnancy is planned or confirmed. One contraindication should already have been screened before starting: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2), which carries a boxed warning on the FDA-approved injectable forms of both semaglutide and tirzepatide. Suspected pancreatitis or severe, persistent vomiting is a reason to stop promptly and contact your clinician rather than taper slowly (FDA prescribing information).
Diabetic patients using GLP-1 therapy for weight management should coordinate any pause or stop with the clinician managing their glycemia, because blood-sugar control typically loosens as the drug clears. Sudden or severe abdominal pain, persistent vomiting, or symptoms suggestive of gallbladder disease warrant contacting your clinician before the next scheduled dose. Signs of significant dehydration from GI side effects — reduced urine output, dizziness — are another reason to stop and seek care (Wegovy prescribing information).
What else clinicians weigh: in people with established cardiovascular disease and obesity but without diabetes, the SELECT trial found that semaglutide 2.4 mg reduced major cardiovascular events versus placebo (HR 0.80; 6.5% vs 8.0% over a mean 39.8 months) (Lincoff 2023, PMID 37952131). That is one of several factors a clinician weighs when individualizing a stay-or-step-down plan — not a reason for any individual to start or keep taking a medication on their own.
Protecting Muscle Through a Taper or Stop
Body-composition substudies of the STEP 1 trial show that a meaningful share of the weight lost is lean tissue rather than fat — the substudy reported an absolute reduction in total lean body mass of about 10%, though the proportion of lean tissue relative to total body mass actually rose because fat loss was larger (King et al., J Endocr Soc 2021). This is in line with what is expected from any substantial caloric deficit. That raises the stakes for how you come off, because weight regained after stopping is not guaranteed to return as the same tissue you lost. The practical goal is to protect muscle on the way down and, if weight does return, to bias it toward fat rather than further muscle loss.
The levers are well established in clinical practice and do not change whether you are tapering or staying on:
Protein. Most clinicians target roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day during and after weight loss — higher than the standard dietary reference — to give muscle the raw material to hold (Bauer et al., PROT-AGE, JAMDA 2013). For people with a BMI over 30, clinicians typically calculate this against an adjusted (rather than actual) body weight, so the target is not overstated.
Resistance training at least twice weekly, ideally three. Walking supports general health but does not preserve muscle the way loading it does. This is the single highest-yield habit to build before a taper, not after.
A gradual rate of change. Aggressively rapid loss, and abrupt swings after stopping, both tend to come at the cost of lean tissue. Slower is more durable.
A program that helps someone stop a GLP-1 without addressing muscle is doing half the job. The medication decision and the body-composition plan are the same conversation.
What Real Monitoring Looks Like in the Maintenance Phase
This is where physician-led care visibly differs from a renew-the-prescription model. Maintenance and tapering are exactly the stages that benefit from oversight, because they are where the plan is most likely to drift.
A reasonable maintenance program looks like this. Body composition is tracked over time — not just the number on the scale, but the trend in lean versus fat mass where measurement is available — so that quiet muscle loss is caught early. Labs from the initial metabolic assessment are rechecked on a sensible cadence — fasting glucose and HbA1c, a lipid panel, liver enzymes, and a basic metabolic panel — typically at baseline, around three months, and then every six to twelve months in maintenance, because these are the measures the STEP 1 extension showed drift back when treatment stops. Dose is adjusted to the lowest level that holds the result rather than left on autopilot. And there are scheduled check-ins built around the transition itself, so that a step-down is a supervised experiment with a feedback loop, not a guess made alone.
How Leader Health Approaches This
At Leader Health, the maintenance decision is treated as part of the medical program, not an afterthought. From the start, your plan includes how you would step down or stop — not just how you begin. Your care includes a metabolic assessment, body-composition and lab monitoring through every phase, protein and training guidance built around preserving muscle, and dose adjustment toward the lowest effective level rather than a renew-on-repeat prescription.
If you have been wondering whether you will be on a GLP-1 forever, that is exactly the conversation worth having before you start — or before you stop. The willingness to plan the off-ramp is part of what physician-led care is for.
References
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470. pubmed.ncbi.nlm.nih.gov/35441470/
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. pubmed.ncbi.nlm.nih.gov/38078870/
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728. pubmed.ncbi.nlm.nih.gov/33755728/
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. pubmed.ncbi.nlm.nih.gov/37952131/
FDA. Wegovy (semaglutide) injection — Prescribing Information (chronic weight management). 2024. accessdata.fda.gov/drugsatfda_docs/label/
FDA. Zepbound (tirzepatide) injection — Prescribing Information (chronic weight management). 2024. accessdata.fda.gov/drugsatfda_docs/label/
FDA. Press Release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. March 3, 2026. fda.gov/news-events/
FDA. Statement on Compounding Following Resolution of GLP-1 Supply Shortages. 2026. fda.gov/drugs/
King S, et al. STEP 1 body-composition substudy (semaglutide, DEXA). J Endocr Soc. 2021. PMC8089287. pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. PMID: 25590212. pubmed.ncbi.nlm.nih.gov/25590212/
Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE Study Group position paper. J Am Med Dir Assoc. 2013;14(8):542-559. PMID: 23867520. pubmed.ncbi.nlm.nih.gov/23867520/
Key takeaways
GLP-1 receptor agonists work by continuously replacing a hormone signal your body makes after eating. When the medication stops, the signal stops — which is why appetite and weight tend to return rather than stay fixed in place.
In the STEP 1 trial extension, people who stopped semaglutide regained about two-thirds of their lost weight within a year, and most of the cardiometabolic improvements drifted back toward baseline (Wilding 2022).
This is increasingly understood as the biology of a chronic condition, not a personal failure. The honest question is not "how do I get off this?" but "what does the maintenance phase look like, and who is monitoring it?"
There is a real difference between stopping abruptly and tapering under supervision — with attention to protein, resistance training, body composition, and labs. The plan around the decision is what matters most.
When GLP-1 therapy stops, the hormonal signal it replaces stops with it — and for most people, appetite and weight return. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight in the year after stopping semaglutide, with most cardiometabolic improvements drifting back toward baseline (Wilding 2022).
If you are on a GLP-1 medication and the question in the back of your mind is "do I have to be on this forever?" — you are asking the most honest question in weight care. It is the single most common concern competitor pages now lead with, and for good reason. Nobody wants to feel tethered to a weekly injection indefinitely.
The reflex answer from the internet is either reassurance or alarm. The clinical reality is more useful than either: these medications were designed for ongoing use, the evidence on abrupt stopping is clear and not especially comforting, and there is a meaningful difference between walking away from the medication and stepping down from it with a plan. This is a guide to that decision — what the trials actually show, and what a monitored maintenance phase looks like.
Why These Medications Work Only While You Take Them
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It does several things at once: it slows the rate at which your stomach empties, it signals fullness to the brain, and it quiets the background "food noise" — the low-grade preoccupation with the next meal that drives much of overeating. Semaglutide is an engineered version of this GLP-1 signaling; tirzepatide acts on the GLP-1 receptor and a second related receptor (GIP). Both are built to last about a week per dose instead of minutes.
Here is the part that explains everything about stopping. The medication does not retrain your physiology to a new permanent set point. It supplies a signal that your body, in a state of excess weight, does not produce strongly enough on its own. While the drug is present, appetite is lower and the food noise is quieter. When the drug clears, the underlying signaling returns to where it was — and so, for most people, do appetite and weight. The biological story is simple: the medication manages the condition; it does not cure it.
This is why endocrinologists increasingly frame obesity the way they frame hypertension or type 2 diabetes — as a chronic condition where the treatment works for as long as it is used, not a course you complete (Endocrine Society clinical practice guideline, 2015). A blood pressure medication is not a failure because the numbers rise again after you stop it. The same logic applies here.
What the Trials Show When People Stop
Three randomized trials have looked directly at what happens when GLP-1 therapy is continued versus withdrawn. The evidence is consistent.
In the STEP 1 trial extension, adults who had lost an average of 17.3% of their body weight on semaglutide had the medication and the lifestyle support withdrawn, then were followed for another year. They regained 11.6 percentage points of the weight they had lost — roughly two-thirds of it — leaving a net loss of about 5.6% from where they started. Improvements in blood pressure, lipids, and blood sugar largely reverted toward baseline over the same period (Wilding 2022, PMID 35441470). The trial's own authors concluded that the findings "confirm the chronicity of obesity" and that ongoing treatment is required to maintain the benefit.
Two withdrawal trials show the mirror image — what continuing does. In SURMOUNT-4, participants who reached an average 20.9% weight reduction over a 36-week open-label lead-in on tirzepatide were randomized either to stay on it or switch to placebo for a year. Those who continued lost a further 5.5%; those who switched to placebo regained 14.0% (Aronne 2024, PMID 38078870). Nearly nine in ten people who stayed on treatment held onto at least 80% of their initial loss, versus about one in six who stopped. STEP 4 found the same pattern with semaglutide: over the 48 weeks after randomization, continuing produced a further 7.9% loss, while switching to placebo produced a 6.9% weight gain, with waist circumference and blood pressure tracking in the same direction (Rubino 2021, PMID 33755728).
Two important caveats keep this honest. These are averages, and individual variation is considerable — some people hold their weight better than the means suggest, and a smaller number do worse. And the regain seen in these trials followed abrupt discontinuation with limited structured support; it is not a verdict on what a planned, monitored step-down can achieve, which has been less studied. What the data do establish is the direction: for most people, the weight comes back when the signal goes away.
Pause, Taper, or Stop — How the Decision Actually Gets Made
"Stopping" is not one decision. In practice there are three distinct paths, and the right one depends on why someone wants off and where they are in their progress.
Continue at a maintenance dose. For many people who have reached their goal, the appropriate move is not to stop but to settle onto the lowest dose that holds the result. The maintenance phase is a real clinical stage, not a holding pattern — the aim is the smallest effective dose with the fewest side effects.
Taper under supervision. For those who do want to come off — because of cost, side effects, pregnancy planning, or simple preference — a gradual step-down is more sensible than an abrupt stop. Tapering gives the clinical team time to watch what happens to appetite, weight, and labs at each lower dose, and to pause the descent if regain accelerates. It also creates a window to reinforce the non-medication scaffolding that has to carry more of the load: protein, training, sleep, and structure. Because these medications are not used in pregnancy and clear slowly, manufacturer guidance is to stop semaglutide at least two months before a planned pregnancy (FDA prescribing information).
Stop, with a monitored landing. Sometimes stopping fully is the right call — a goal met and held, a side effect that outweighs the benefit, or a life circumstance that requires it. Even then, stopping is a managed process rather than an event. A reasonable question to ask any prescribing program at the start is what stepping down or stopping would look like — the answer is part of how you choose where to get care.
Cost and access changes are common reasons patients consider stopping — a physician-led program should help you evaluate whether a lower maintenance dose, a therapeutic switch, or a supervised step-down best fits your situation, and confirm you are on an FDA-approved product.
When Stopping Is the Medically Right Call
Some situations make pausing or stopping the medically appropriate choice, and a good program names them up front. Stopping is warranted for persistent or severe gastrointestinal symptoms, suspected pancreatitis, gallbladder disease, or severe gastroparesis, and the medication should be stopped when pregnancy is planned or confirmed. One contraindication should already have been screened before starting: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2), which carries a boxed warning on the FDA-approved injectable forms of both semaglutide and tirzepatide. Suspected pancreatitis or severe, persistent vomiting is a reason to stop promptly and contact your clinician rather than taper slowly (FDA prescribing information).
Diabetic patients using GLP-1 therapy for weight management should coordinate any pause or stop with the clinician managing their glycemia, because blood-sugar control typically loosens as the drug clears. Sudden or severe abdominal pain, persistent vomiting, or symptoms suggestive of gallbladder disease warrant contacting your clinician before the next scheduled dose. Signs of significant dehydration from GI side effects — reduced urine output, dizziness — are another reason to stop and seek care (Wegovy prescribing information).
What else clinicians weigh: in people with established cardiovascular disease and obesity but without diabetes, the SELECT trial found that semaglutide 2.4 mg reduced major cardiovascular events versus placebo (HR 0.80; 6.5% vs 8.0% over a mean 39.8 months) (Lincoff 2023, PMID 37952131). That is one of several factors a clinician weighs when individualizing a stay-or-step-down plan — not a reason for any individual to start or keep taking a medication on their own.
Protecting Muscle Through a Taper or Stop
Body-composition substudies of the STEP 1 trial show that a meaningful share of the weight lost is lean tissue rather than fat — the substudy reported an absolute reduction in total lean body mass of about 10%, though the proportion of lean tissue relative to total body mass actually rose because fat loss was larger (King et al., J Endocr Soc 2021). This is in line with what is expected from any substantial caloric deficit. That raises the stakes for how you come off, because weight regained after stopping is not guaranteed to return as the same tissue you lost. The practical goal is to protect muscle on the way down and, if weight does return, to bias it toward fat rather than further muscle loss.
The levers are well established in clinical practice and do not change whether you are tapering or staying on:
Protein. Most clinicians target roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day during and after weight loss — higher than the standard dietary reference — to give muscle the raw material to hold (Bauer et al., PROT-AGE, JAMDA 2013). For people with a BMI over 30, clinicians typically calculate this against an adjusted (rather than actual) body weight, so the target is not overstated.
Resistance training at least twice weekly, ideally three. Walking supports general health but does not preserve muscle the way loading it does. This is the single highest-yield habit to build before a taper, not after.
A gradual rate of change. Aggressively rapid loss, and abrupt swings after stopping, both tend to come at the cost of lean tissue. Slower is more durable.
A program that helps someone stop a GLP-1 without addressing muscle is doing half the job. The medication decision and the body-composition plan are the same conversation.
What Real Monitoring Looks Like in the Maintenance Phase
This is where physician-led care visibly differs from a renew-the-prescription model. Maintenance and tapering are exactly the stages that benefit from oversight, because they are where the plan is most likely to drift.
A reasonable maintenance program looks like this. Body composition is tracked over time — not just the number on the scale, but the trend in lean versus fat mass where measurement is available — so that quiet muscle loss is caught early. Labs from the initial metabolic assessment are rechecked on a sensible cadence — fasting glucose and HbA1c, a lipid panel, liver enzymes, and a basic metabolic panel — typically at baseline, around three months, and then every six to twelve months in maintenance, because these are the measures the STEP 1 extension showed drift back when treatment stops. Dose is adjusted to the lowest level that holds the result rather than left on autopilot. And there are scheduled check-ins built around the transition itself, so that a step-down is a supervised experiment with a feedback loop, not a guess made alone.
How Leader Health Approaches This
At Leader Health, the maintenance decision is treated as part of the medical program, not an afterthought. From the start, your plan includes how you would step down or stop — not just how you begin. Your care includes a metabolic assessment, body-composition and lab monitoring through every phase, protein and training guidance built around preserving muscle, and dose adjustment toward the lowest effective level rather than a renew-on-repeat prescription.
If you have been wondering whether you will be on a GLP-1 forever, that is exactly the conversation worth having before you start — or before you stop. The willingness to plan the off-ramp is part of what physician-led care is for.
References
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470. pubmed.ncbi.nlm.nih.gov/35441470/
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. pubmed.ncbi.nlm.nih.gov/38078870/
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728. pubmed.ncbi.nlm.nih.gov/33755728/
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. pubmed.ncbi.nlm.nih.gov/37952131/
FDA. Wegovy (semaglutide) injection — Prescribing Information (chronic weight management). 2024. accessdata.fda.gov/drugsatfda_docs/label/
FDA. Zepbound (tirzepatide) injection — Prescribing Information (chronic weight management). 2024. accessdata.fda.gov/drugsatfda_docs/label/
FDA. Press Release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. March 3, 2026. fda.gov/news-events/
FDA. Statement on Compounding Following Resolution of GLP-1 Supply Shortages. 2026. fda.gov/drugs/
King S, et al. STEP 1 body-composition substudy (semaglutide, DEXA). J Endocr Soc. 2021. PMC8089287. pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. PMID: 25590212. pubmed.ncbi.nlm.nih.gov/25590212/
Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE Study Group position paper. J Am Med Dir Assoc. 2013;14(8):542-559. PMID: 23867520. pubmed.ncbi.nlm.nih.gov/23867520/
In this article
Frequently Asked Questions
Not necessarily, but you should plan as if the answer could be "for a long time." These medications manage weight while they are taken; for most people, appetite and weight return after stopping. Some people maintain on a low dose, some taper off successfully with strong lifestyle support, and the right path is an individual decision made with a clinician.
In the STEP 1 trial extension, people regained about two-thirds of their lost weight in the year after stopping semaglutide (Wilding 2022). That is an average from abrupt discontinuation — individual results vary, and a planned, supported step-down is less studied. The honest expectation is that some regain is likely without an active maintenance plan.
For most people using GLP-1 therapy for weight management, stopping abruptly is not medically dangerous in the way missing a cardiac medication can be — but it is the version most associated with rapid regain and the return of cardiometabolic risk factors toward baseline. For anyone using a GLP-1 for type 2 diabetes, or in combination with insulin or a sulfonylurea, do not stop without coordinating with the prescribing clinician, because blood-sugar control can shift quickly.
Many people do pause and restart, often around cost, supply, or life events. The main thing to expect is that the appetite-suppressing effect fades during the break and weight may climb, then returns when you resume. Restarting usually means re-titrating from a lower dose to manage side effects, which is a conversation to have with your prescriber rather than a do-it-yourself decision. Restarting also means confirming with your clinician that you are receiving an FDA-approved product appropriate for your situation.
The bigger muscle risk is during active weight loss, when a meaningful share of what you lose is lean tissue. When you stop, the concern shifts to what regained weight is made of. Keeping protein high (roughly 1.2–1.6 g/kg per day) and resistance training at least twice a week is the best-supported way to protect muscle through the transition.
It is the lowest dose that holds your result with the fewest side effects, used once you have reached your goal rather than to keep losing. There is no single correct number — it is set individually and adjusted over time, which is exactly the kind of decision that benefits from ongoing monitoring rather than a fixed prescription.
There is no good randomized evidence that hormone therapy and GLP-1 medications interfere with each other, and in practice they are often managed together — particularly in perimenopause, when shifting hormones and metabolic changes overlap. What matters is that one clinician oversees both, so dosing, labs, and side effects are read as a single plan rather than in isolation.
About Medical Reviewer
About Medical Reviewer
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD, MBA
CMO of Leader Health
All related stories post
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
Hormone Therapy
Sexual health
Weight Loss & Longevity
Diagnostic Labs
Company
Take Action
More From Leader
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION